InMed Pharmaceuticals does not expect that the COVID-19 pandemic to significantly affect data collection in its Phase 1…
Articles by Marisa Wexler, MS
Using mesenchymal stem cells to treat adults with recessive dystrophic epidermolysis bullosa (RDEB) appears to be safe and may…
The investigational oral treatment Serlopitant may be able to reduce itching in people with epidermolysis bullosa (EB), results…
New guidelines on foot care for people with epidermolysis bullosa (EB) highlight the benefits of proper care and footwear,…
A novel gene editing technique was able to correct mutations in COL7A1 in cells taken from people with recessive dystrophic…
EB-101, a cell therapy candidate from Abeona Therapeutics, induced sustained wound healing lasting for three years or more in a…
A specific class of T cells – called Th17 cells — may drive inflammation in patients with epidermolysis bullosa simplex…